- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06350565
A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Two studies will be conducted both of which are single-centre, open clinical studies. It is proposed to collect maternal blood, umbilical vein blood and placental tissue from pregnant women treated with dexamethasone, which excludes early placental detachment, use of surfactant, severe intrauterine haemorrhage, or pregnant women who meet the conditions of the exclusion criteria. Determination and implementation of dexamethasone treatment regimen will be carried out by clinicians in accordance with the treatment guidelines, and the collection of samples will be carried out in the form of opportunistic blood sampling or placenta collection after normal diagnostic and therapeutic operations of pregnant women except for 2 active collections of blood after dosing; this study will not interfere with the normal maternal pregnancy, labour and diagnostic and therapeutic processes.
Half-dose study: A total of 24 Chinese pregnant subjects with 34+0-35+6 GW requiring dexamethasone treatment for preterm labour with preterm prematurity in China were planned to be enrolled in this study. A total of 12 subjects receiving 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the full-dose group; 12 subjects receiving 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the half-dose group.
EXPLORATORY STUDY: This study was planned to enrol 24 pregnant women with 34+0-38+6 GW preterm labour with confirmed gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy in a dose exploratory study in this population. A total of 12 subjects were enrolled in the full-dose group to receive 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) and 12 subjects were enrolled in the half-dose group to receive 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dongyang Liu
- Phone Number: 18610966092
- Email: liudongyang@vip.sina.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Common criteria for half-dose studies and exploratory studies:
- Age 18-40 years (inclusive);
- Body mass index (BMI) 18.5-27.9 kg/m2 (inclusive).
- risk of preterm labour and use of dexamethasone for fetal lung maturation.
Half-dose study-specific criteria:
(1) Greater than or equal to 34+0 gestational weeks and less than or equal to 35+6 gestational weeks at enrolment;
Exploratory study-specific criteria:
- Greater than or equal to 34+0 gestational weeks and less than or equal to 38+6 gestational weeks at enrolment;
- Confirmed diagnosis of GDM or having diabetes mellitus.
Exclusion Criteria:
- Multiple pregnancies (three or more pregnancies)
- For subjects who are unable to be included in this study in the following cases:
- Pregnant women with ectopic pregnancy
- Fetal distress, severe infectious (e.g. sepsis, infectious shock) disease, fever;
- Those who have taken glucocorticoid drugs within 2 weeks before joining the clinical trial;
- Those who took clindamycin during the study period;
- Those with congenital foetal anomalies or foetal hypoxia occurring in early pregnancy;
- Patients with convulsions;
- Those with a history of HIV/HCV/hepatitis A, substance abuse;
- Chorioamnionitis, endometritis;
- Placental abruption, use of surfactant, severe intrauterine haemorrhage;
- Pregnant women with cervical dilatation greater than or equal to 4 cm or ultrasonographic neck length greater than or equal to 20 mm;
- Pregnant women taking food or drugs during the study period that may affect foetal safety;
- Pregnant women participating in other clinical trials.
- Gestational diabetes mellitus and patients with diabetes mellitus (exclusion criteria for half-dose studies only).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Half-dose study
A total of 24 Chinese pregnant subjects with 34+0-35+6 GW requiring dexamethasone treatment for preterm labour with preterm prematurity in China were planned to be enrolled in this study.
A total of 12 subjects receiving 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the full-dose group; 12 subjects receiving 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses) were enrolled in the half-dose group.
|
This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions.
During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
|
Other: An exploratory study
This study was planned to enrol 24 pregnant women with 34+0-38+6 GW preterm labour with confirmed gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy in a dose exploratory study in this population.
A total of 12 subjects were enrolled in the full-dose group to receive 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) and 12 subjects were enrolled in the half-dose group to receive 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses).
|
This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions.
During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory distress syndrome
Time Frame: Detection and evaluation of the newborn within 24 hours of the end of delivery
|
Dependent on clinical presentation, arterial blood gas analysis, and chest X-ray.
(1) progressive dyspnoea, expiratory groaning, inspiratory trigonocephaly, cyanosis, and markedly reduced or absent breath sounds on lung auscultation that appeared shortly after birth; (2) lung X-ray changes typical of RDS, with diffuse fine-grained reticulated ground-glass shadows accompanied by bronchial insufflation signs; and (3) exceptions to dyspnoea caused by simple severe pneumonia, meconium aspiration or pulmonary haemorrhage, etc.
|
Detection and evaluation of the newborn within 24 hours of the end of delivery
|
PK parameters (analysed in conjunction with population pharmacokinetic (PPK) modelling): area under the blood concentration curve, Cmax, Tmax, Kel, t1/2, CL, VZ
Time Frame: 2±0.5 h, 12 h after first dose
|
Blood concentrations of dexamethasone and its metabolites and foetal blood concentrations
|
2±0.5 h, 12 h after first dose
|
Pharmacodynamics
Time Frame: In the course of pregnancy (GW8-delivery), the blood samples were collected every 2 weeks on average, and the blood samples were collected during each delivery and at the time of delivery, and the exact time of delivery was slightly adjusted according to
|
Biomarker assay and measurement of placental P-gp regulatory sensitive factor pregnancy blood concentrations.
|
In the course of pregnancy (GW8-delivery), the blood samples were collected every 2 weeks on average, and the blood samples were collected during each delivery and at the time of delivery, and the exact time of delivery was slightly adjusted according to
|
Measurability indicators
Time Frame: during labour
|
Measurable indicators: neonatal head circumference, length, weight, blood pressure (diastolic/systolic);
|
during labour
|
Blood biochemistry findings in newborns
Time Frame: during labour
|
Blood glucose concentration, blood triglyceride concentration, etc.
|
during labour
|
DEX potential safety marker test
Time Frame: during labour
|
Maternal blood and umbilical vein blood were collected at the time of delivery and concentrations of potentially toxic biomarkers (e.g.
ACTH, CORT, GABA, GAD67) were measured
|
during labour
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Infant, Premature, Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Premature Birth
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Obstetric Labor, Premature
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- DEX20240104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome of Newborn
-
The First Affiliated Hospital with Nanjing Medical...UnknownRespiratory Distress Syndrome of NewbornChina
-
Zagazig UniversityRecruitingof Lung Ultrasound in Diagnosis of Acute Respiratory Distress SyndromeEgypt
-
University of Wisconsin, MadisonUnityPoint Health-MeriterRecruiting
-
Unity Health TorontoRecruitingRespiratory Distress Syndrome | RDS of Prematurity | TTN | Respiratory Distress, NewbornCanada
-
Ministry of Health, Sri LankaCompletedRespiratory Distress of NewbornSri Lanka
-
Hospital General Universitario Gregorio MarañonNot yet recruitingRespiratory Distress Syndrome of Prematurity
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Dr Anna Lavizzari; Dr Francesca Gaia CiuffiniCompletedNewborn Respiratory Distress SyndromeItaly
-
Karolinska InstitutetCompletedRespiratory Distress Syndrome, Newborn | Infant, Newborn | Respiratory Insufficiency Syndrome of NewbornSweden
-
Zekai Tahir Burak Women's Health Research and Education...UnknownTransient Tachypnea of NewbornTurkey
-
University of CologneCompletedTransient Tachypnoea of the NewbornGermany
Clinical Trials on Dexamethasone
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Universidade Federal de PernambucoCompletedDiabetic Macular EdemaBrazil
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Shanghai Jiao Tong University Affiliated Sixth...CompletedAnalgesia | Time | Brachial Plexus Block | Shoulder Surgery | Dexamethasone | Intravenous Drug UsageChina
-
Poznan University of Medical SciencesRecruitingWrist Injuries | Hand Injuries | Hand Injuries and Disorders | Hand Disease | Wrist DiseasePoland
-
University of California, San FranciscoCompletedOral Lichen Planus | Pemphigus Vulgaris | Mucous Membrane Pemphigoid | Chronic Graft-versus-host-diseaseUnited States
-
University of BelgradeCompleted